Education
About Us
Working with TipRanks
Follow Us
Mediwound (MDWD)
NASDAQ:MDWD
Top Page
Mediwound
(NASDAQ:MDWD)
Select Model
Select Model
Rating:48Neutral
Price Target:
$18.50
▲(7.25% Upside)
Mediwound's overall stock score reflects significant challenges in financial performance and valuation, with ongoing profitability issues and cash flow difficulties. Technical analysis shows mixed signals, while the earnings call provides some optimism with strategic advancements and partnerships. The company's growth potential is evident, but financial health improvements are crucial for a more favorable outlook.
Positive Factors
Strategic Partnerships
These partnerships enhance Mediwound's market reach and bolster its R&D capabilities, potentially accelerating product development and market penetration.
Revenue Growth in U.S. Market
Strong revenue growth in the U.S. indicates successful market expansion and increasing adoption of NexoBrid, supporting long-term revenue stability.
Strong Cash Position
A robust cash position provides Mediwound with the financial flexibility to invest in R&D and strategic initiatives, ensuring sustained growth and innovation.
Negative Factors
Increased Net Loss
The significant net loss highlights ongoing profitability challenges, which could strain resources and affect long-term financial health if not addressed.
R&D and SG&A Expense Increases
Rising expenses in R&D and SG&A could pressure margins and delay profitability, impacting the company's ability to invest in growth opportunities.
Slight Revenue Decrease in First Half 2025
A decline in revenue, even slight, suggests potential challenges in maintaining consistent growth, which could affect investor confidence and strategic planning.
Mediwound (MDWD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$180.60M
Dividend YieldN/A
Average Volume (3M)129.50K
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue Growth-1.41%
EPS Growth-22.05%
CountryUS
Employees111
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.23
Shares Outstanding10,807,726
10 Day Avg. Volume200,770
30 Day Avg. Volume129,495
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue9.38
Enterprise Value/Gross Profit50.91
Enterprise Value/Ebitda-6.08
Forecast
1Y Price Target
$30.00Price Target Upside73.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Mediwound Business Overview & Revenue Model
Company DescriptionMediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
How the Company Makes MoneyMediwound generates revenue through the sale of its core products, primarily NexoBrid, which is marketed for the treatment of severe burns and other wounded tissues. The company also earns income from licensing agreements and collaborations with larger pharmaceutical firms, allowing it to expand its market reach and product offerings. Key revenue streams include direct sales to healthcare facilities, distribution agreements in various countries, and potential royalties from partners that utilize Mediwound's technology in their own product lines. Additionally, Mediwound may benefit from government grants and funding aimed at advancing medical innovations, further contributing to its financial performance.
Mediwound Earnings Call Summary
Earnings Call Date:Aug 14, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 18, 2025
Earnings Call Sentiment Neutral
MediWound's earnings call presented both significant progress and challenges. Highlights included strong progress in clinical trials, partnerships, and revenue growth in the U.S. market for NexoBrid. However, the company faced increased net loss and higher expenses affecting financial performance. Despite these challenges, strategic advancements and collaborations position MediWound for future growth.Q2-2025 Updates
Positive Updates
EscharEx VALUE Phase III Trial Progress
The EscharEx VALUE Phase III trial is actively enrolling patients, with plans to enroll 216 patients across 40 sites in the U.S. and Europe. New collaborations with Convatec and Essity support the ongoing VLU trial and planned DFU trial.
NexoBrid U.S. Market Expansion
NexoBrid continues to gain traction in the U.S. market, with a reported 52% year-over-year revenue growth driven by increased hospital unit orders and the number of ordering centers.
Financial Growth in Q2 2025
Second quarter revenue grew 43% sequentially, with total revenue reaching $5.7 million, up from $5.1 million in Q2 2024. Gross profit was $1.3 million or 23.5% of revenue, compared to $0.4 million or 8.8% in the prior year.
Additional Funding from U.S. Department of Defense
MediWound was awarded an additional $3.6 million in non-dilutive funding from the U.S. Department of Defense, bringing total program funding to $18.2 million for a room temperature-stable formulation of NexoBrid.
Strong Cash Position
As of June 30, 2025, MediWound had $32.9 million in cash, cash equivalents, and deposits, providing financial flexibility to advance key programs.
Negative Updates
Increased Net Loss
Net loss was $13.3 million or $1.23 per share in Q2 2025, compared to a net loss of $6.3 million or $0.68 per share in the same period last year, driven by $6.6 million in noncash financial expenses.
R&D and SG&A Expense Increases
Research and development expenses rose to $3.5 million from $1.9 million in Q2 2024, and SG&A expenses increased to $3.6 million from $3 million last year, affecting overall financials.
Slight Revenue Decrease in First Half 2025
Total revenue for the first half of 2025 was $9.7 million, slightly down from $10 million in the first half of 2024, primarily due to lower BARDA-funded development revenue.
Operational Loss Increase
Operating loss increased to $5.7 million in Q2 2025, up from $4.5 million in Q2 2024, reflecting higher expenses and slower revenue growth.
Company Guidance
During the MediWound Second Quarter 2025 Earnings Conference Call, the company provided comprehensive guidance on its ongoing and forthcoming projects. Key updates included the active enrollment of patients in the EscharEx VALUE Phase III trial, targeting 216 patients across 40 sites, with an expected interim sample size assessment by mid-2026. The company has established new collaborations with leading wound care companies such as Convatec and Essity to support the VALUE and planned DFU trials. Additionally, MediWound reported a 52% year-over-year revenue growth for NexoBrid in the U.S., driven by increased hospital unit orders and the number of ordering centers. The commissioning of a new manufacturing facility is on track for completion by year-end, with regulatory approvals expected in the first and second halves of 2026 for EMA and FDA, respectively. Financially, MediWound's second-quarter revenue was $5.7 million, a 43% sequential increase, while net loss was $13.3 million, impacted by noncash financial expenses. The company reported $32.9 million in cash and equivalents as of June 30, 2025, with potential proceeds of up to $32 million from Series A warrants. MediWound's strategic focus remains on advancing the EscharEx trial, completing the manufacturing scale-up, and building global recognition through clinical collaborations and publications.Mediwound Financial Statement Overview
Summary
Mediwound's financial statements reflect growth potential but significant challenges in profitability and cash flow management. Revenue is growing, but margins are under pressure, and the company is not yet profitable. The balance sheet is stable with manageable leverage, but returns on equity are negative. Cash flow issues are a major concern, requiring strategic improvements to enhance financial health.Income Statement
Mediwound's income statement shows a modest revenue growth rate of 3.36% TTM, indicating some positive momentum. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin is relatively low at 18.43%, reflecting challenges in cost management. Overall, the income statement reflects a company with growth potential but significant profitability issues.45
Neutral
Balance Sheet
The balance sheet reveals a moderate debt-to-equity ratio of 0.40 TTM, suggesting manageable leverage levels. However, the return on equity is negative, indicating that the company is not generating sufficient returns on shareholders' equity. The equity ratio stands at 30.03%, showing a reasonable level of equity financing. Overall, the balance sheet is stable but highlights concerns about profitability and return generation.50
Neutral
Cash Flow
The cash flow statement indicates a significant challenge with negative operating cash flow and free cash flow. The free cash flow growth rate is positive at 86.9% TTM, but this is from a low base. The operating cash flow to net income ratio is negative, reflecting cash flow difficulties. Overall, the cash flow position is weak, with improvements needed in cash generation and management.40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.86M | 20.22M | 18.69M | 26.50M | 23.76M | 21.76M |
| Gross Profit | 3.66M | 2.63M | 3.58M | 13.16M | 8.77M | 7.54M |
| EBITDA | -30.62M | -28.12M | -4.89M | -18.09M | -11.38M | -7.35M |
| Net Income | -28.23M | -30.22M | -6.72M | -19.60M | -13.55M | -9.20M |
Balance Sheet | ||||||
| Total Assets | 67.00M | 73.50M | 66.46M | 50.02M | 19.74M | 31.07M |
| Cash, Cash Equivalents and Short-Term Investments | 32.44M | 43.16M | 41.54M | 33.90M | 11.05M | 21.58M |
| Total Debt | 8.07M | 6.93M | 6.35M | 846.00K | 1.39M | 1.74M |
| Total Liabilities | 46.88M | 42.34M | 34.86M | 39.10M | 24.33M | 23.80M |
| Stockholders Equity | 20.12M | 31.15M | 31.59M | 10.91M | -4.58M | 7.27M |
Cash Flow | ||||||
| Free Cash Flow | -19.27M | -19.90M | -16.93M | -12.44M | -9.40M | -7.82M |
| Operating Cash Flow | -15.26M | -13.62M | -10.46M | -11.88M | -8.92M | -6.89M |
| Investing Cash Flow | -7.90M | -8.40M | -34.32M | -481.00K | 3.55M | 17.39M |
| Financing Cash Flow | 20.38M | 19.39M | 22.92M | 35.76M | -1.05M | -629.00K |
Mediwound Technical Analysis
Negative
17.25
Price Trends
18.42
Negative
19.09
Negative
18.32
Negative
Market Momentum
-0.26
Negative
47.55
Neutral
22.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDWD, the sentiment is Negative. The current price of 17.25 is above the 20-day moving average (MA) of 17.12, below the 50-day MA of 18.42, and below the 200-day MA of 18.32, indicating a neutral trend. The MACD of -0.26 indicates Negative momentum. The RSI at 47.55 is Neutral, neither overbought nor oversold. The STOCH value of 22.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MDWD.
Mediwound Risk Analysis
Mediwound disclosed 58 risk factors in its most recent earnings report. Mediwound reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Mediwound Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | 317.42M | -8.49 | -84.55% | ― | 76.43% | -35.66% | |
48 Neutral | $180.60M | ― | -148.65% | ― | -1.41% | -22.05% | |
47 Neutral | 338.84M | -5.59 | 0.00% | ― | 0.00% | -24.60% | |
41 Neutral | 164.72M | -1.42 | 0.00% | ― | 0.00% | 39.76% | |
35 Underperform | 145.51M | -1.97 | 0.00% | ― | 0.00% | 0.00% | |
33 Underperform | 165.23M | -4.50 | 0.00% | ― | 0.00% | -406.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
MDWD
Mediwound
17.25
-0.47
-2.65%
LCTX
Lineage Therap
1.55
0.64
70.33%
ELDN
Eledon Pharmaceuticals
2.55
0.07
2.82%
DSGN
Design Therapeutics
6.25
0.39
6.66%
VTYX
Ventyx Biosciences
2.39
0.02
0.84%
TVGN
Tevogen Bio Holdings
0.82
0.38
86.36%
Mediwound Corporate Events
MediWound Executives Purchase Shares, Signaling Confidence
Aug 19, 2025
On August 18, 2025, MediWound Ltd. announced that its Chairman, Mr. Nachum (Homi) Shamir, and CEO, Mr. Ofer Gonen, purchased a total of 11,200 ordinary shares of the company in open market transactions. These purchases, made at an average price of $17.74 per share, were conducted in accordance with the company’s insider trading policy, reflecting confidence in the company’s future prospects and potentially influencing stakeholder perceptions positively.
MediWound Reports Q2 2025 Financial Results and Strategic Updates
Aug 14, 2025
On August 14, 2025, MediWound Ltd. announced its financial results for the second quarter of 2025, reporting a 43% increase in revenue from the prior quarter, reaching $5.7 million. The company highlighted ongoing patient enrollment in its VALUE Phase III trial for EscharEx, strategic collaborations with Essity and Convatec, and manufacturing expansion for NexoBrid, which is expected to reach full operational capacity by the end of 2025. Despite a net loss of $13.3 million, MediWound’s financial performance showed improved gross profit margins and increased R&D investments, reflecting confidence in its long-term strategy.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.